Archived Bulletins

June 20, 2018

Published: June 20, 2018
Category: Publications

New results from the groundbreaking “Trial Assigning Individualized Options for Treatment Rx” (TAILORx) breast cancer trial (CCTG MAC.12 in Canada), show no benefit from chemotherapy for 70% of women with the most common form of breast cancer. The study found that for a group of women with hormone receptor (HR)-positive, HER2 negative, axillary lymph node-negative breast cancer, treatment with chemotherapy and hormone therapy after surgery is not more beneficial than with hormone therapy alone.

Read More

June 06, 2018

Published: June 06, 2018
Category: Trials

PNC.1 (EA8134), InPACT: International Penile Advanced Cancer Trial, has been centrally activated in Canada.

Read More

Published: June 06, 2018
Category: Trials

CCTG MA.39 TAILOR RT: A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER has been centrally activated in Canada

Read More

Published: June 06, 2018
Category: Group updates

A great opportunity to join our team: The Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has a job opening for a Monitor/Auditor.

Position Title: Monitor/Auditor
Competition Number: J0518-0333

Read More

Clinical trials are not always about finding a new drugs that works, sometimes they look at what treatments, or what doses, are necessary for patients.

Read More

Study results suggest that a new pancreatic cancer treatment become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery. The randomized phase III clinical trial was sponsored by the academic cancer research groups of UNICANCER, in Paris, France and the Canadian Cancer Trials Group (CCTG). The results show that the risk of cancer recurring in post-operative pancreatic cancer patients was reduced by almost 50% with the mFOLFIRINOX chemotherapy combination.

Read More

Published: June 06, 2018
Category: News

Bladder cancer hit the world stage with an oral presentation at ASCO this past weekend. The presentation of the results of the study was given by Dr. Srikala Sridhar, BL12 Study Chair, at the general meeting in Chicago. Bladder cancer is the 5th most common cancer in Canada with 9000 new cases annually. For patients with advanced disease who progress on first line chemotherapy, options include immunotherapy or taxane-based chemotherapy. 

Read More

May 23, 2018

The Sunnybrook Health Sciences Centre and the Ottawa Hospital are currently enrolling women in the Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare conventional mammography (2-D) to the newer digital tomosynthesis method (3-D).The large scale North American study was developed by the US based ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and the National Cancer Institute (NCI), with the Canadian Cancer Trials Group (CCTG) coordinating the trial in Canada (more national sites will be opening the trial over the next several months).

Read More